Ionis Pharmaceuticals, Inc. revised earnings guidance for the year 2015. The company announced that the Company expects to significantly improve upon its financial guidance for 2015. The Company expects to end 2015 with a pro forma net operating loss (NOL) in the low $20 million range and more than $775 million in cash.

The company expects to end 2015 with a pro forma NOL in the low $20 million range, which represents a 60% improvement over original guidance. In addition, the company expects to end 2015 with more than $775 million in cash, substantially exceeding 2014 year-end cash balance and 2015 cash guidance. Importantly, significant increase in revenue over the last several years reflects the successes in all of collaborations as the drugs in those collaborations advanced.